Tango Therapeutics (TNGX) Net Cash Flow (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Net Cash Flow of $45.1 million for Q1 2026, up 506.57% year-over-year from $7.4 million in Q1 2025, and down 16.35% quarter-over-quarter from $53.9 million in Q4 2025.
Tango Therapeutics (TNGX) Net Cash Flow (2020 - 2026) Analysis & Trends
Tango Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $45.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 506.57% year-over-year to $45.1 million; the TTM figure through Mar 2026 stood at $99.0 million (up 3723.87% YoY), while the FY2025 annual figure was $42.7 million, up 1767.58% from the prior year.
- Net Cash Flow for Q1 2026 stood at $45.1 million, down from $53.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $53.9 million in Q4 2025, with the low at -$41.1 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$3.3 million (2023), against an average of $879000.0.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow plunged 209.93% in 2022, then soared 1105.18% in 2025.
- Tango Therapeutics' Net Cash Flow stood at -$40.3 million in 2022, then soared by 119.46% to $7.9 million in 2023, then soared by 108.63% to $16.4 million in 2024, then jumped by 229.27% to $53.9 million in 2025, then fell by 16.35% to $45.1 million in 2026.
- Business Quant data shows TNGX's Net Cash Flow at $45.1 million in Q1 2026, $53.9 million in Q4 2025, and $19.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 187.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.73 Mn |
| Jun 30, 2026 | 187.73 Mn |
| Mar 31, 2026 | 45.12 Mn |
| Mar 31, 2026 | 45.12 Mn |
| Dec 31, 2025 | 53.94 Mn |
| Dec 31, 2025 | 53.94 Mn |
| Sep 30, 2025 | 19.07 Mn |
| Sep 30, 2025 | 19.07 Mn |
| Jun 30, 2025 | -19.16 Mn |
| Jun 30, 2025 | -19.16 Mn |
| Mar 31, 2025 | -11.10 Mn |
| Mar 31, 2025 | -11.10 Mn |
| Dec 31, 2024 | 16.38 Mn |
| Dec 31, 2024 | 16.38 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | -9.60 Mn |
| Jun 30, 2024 | -9.60 Mn |
| Mar 31, 2024 | -6.08 Mn |
| Mar 31, 2024 | -6.08 Mn |